Melanotan 2 Side Effects Documented in Research — Adverse Events and Safety Signals

The Melanotan 2 side effects record comes from two sources: the small Phase I/II clinical trials (which documented expected pharmacodynamic effects at study doses) and a growing body of case reports describing adverse events in unregulated self-administration contexts. MT-II has not been approved by any regulatory authority. No systematic human safety study exists. All safety information on this page is from published peer-reviewed literature and case series.

Adverse Events in Published Clinical Trials

In the Dorr 1996 Phase I tanning study (n=3), the documented adverse effects at 0.01–0.025 mg/kg subcutaneously included spontaneous penile erections lasting 1–5 hours, transient nausea, somnolence, and fatigue at higher doses.^[1] These were expected pharmacodynamic effects given MT-II's MC4R and MC1R binding profile, not idiosyncratic reactions.

In Wessells 1998 (n=10), transient nausea, yawning, and decreased appetite were the principal adverse effects at 0.025 mg/kg.^[2] In the 2000 expansion (n=20), severe nausea was reported in 12.9% of subjects at the 0.025 mg/kg dose — a rate that places this close to the maximum tolerated dose in this study population.^[3]

Safety Signals Documented in the Research Literature

The post-market case-report literature documents a more serious adverse event profile than the early-phase trials, in part because unregulated use involves higher cumulative doses, variable product purity, and co-administration with UV tanning beds.

MT-II is not approved by any regulatory body. Published case reports document renal infarction, rhabdomyolysis, hypertension, melanoma, dysplastic nevus transformation, and priapism. Regulatory agencies including TGA (Australia) and MHRA (UK) have issued enforcement warnings.

The 2021 Gilhooley qualitative study of 623 online forum posts from 205 MT-II users identified additional risk signals: pigmented skin lesions, infection from unsterile self-injection, polydrug interactions, and widespread misinformation from online sources.^[7] The 2024 Deville forensic analysis confirmed approximately 30% purity in tested illicit MT-II vials^[17], indicating that product contamination is a material confound in any adverse-event attribution.

Renal Observations with Melanotan 2

Peters 2020 describes a 45-year-old male who developed right-sided renal infarction affecting approximately 50% of kidney tissue after self-administering 27 mg of MT-II subcutaneously over six months.^[4] The proposed mechanisms include thrombotic pharmacological influence — MT-II activates sympathetic tone via MC4R, which can affect vascular reactivity — and possible direct nephrotoxic effect. The Swedish Poison Center recorded 215 MT-II exposure cases between January 2008 and May 2019 with no prior renal infarction documented; the Peters 2020 case was the first published instance.

The renal safety observations do not establish causation for typical research-dose ranges (0.01–0.025 mg/kg), but the cumulative dose in this case (27 mg over six months) far exceeds anything studied in controlled trials. Clinicians who encounter patients using MT-II should be aware of the renal and cardiovascular risk signals in the case-report literature.

Melanocytic and Dermatological Adverse Events

MC1R activation by MT-II can stimulate melanocyte proliferation, which represents a risk in individuals with pre-existing dysplastic nevi, familial atypical mole and malignant melanoma (FAMMM) syndrome, or personal or family history of melanoma.

Sivyer 2012 documented a 16-year-old female with FAMMM syndrome who developed multiple dysplastic melanocytic nevi including one with moderate cytoarchitectural atypia after self-administering MT-II alongside UV tanning.^[8] Pigmentation generally reversed three months after cessation.

Hjuler and Lorentzen 2014 reported histologically confirmed melanoma at the left gluteal region in a 20-year-old woman who self-injected MT-II for 3–4 weeks while using tanning beds.^[9] The combination of synthetic MC1R agonism and UV radiation was proposed as a co-stimulatory mechanism for neoplastic transformation.

Hueso-Gabriel 2012 documented eruptive dysplastic nevi following MT-II use in a patient with a history of dysplastic nevi and melanoma.^[20] Histologically atypical features were present. Collectively, these cases constitute a consistent dermatological safety signal: individuals with dysplastic nevus syndrome, FAMMM, or melanoma history face elevated risk from MC1R agonist exposure, particularly in combination with UV radiation.

Priapism: A Serious Sexual Adverse Event

Priapism — prolonged ischemic penile erection — has been documented in case reports following MT-II self-administration. Mallory 2021 described a case of acute ischemic priapism requiring surgical penoscrotal decompression after cavernosal aspiration, irrigation, and intracavernous phenylephrine all failed.^[10] This was identified as the third published case of priapism attributable to MT-II. Ischemic priapism is a urological emergency; resolution within 4–6 hours is required to prevent permanent ischemic damage. The MC4R-mediated pro-erectile mechanism that makes MT-II pharmacologically interesting is the same pathway that produces this serious adverse event at higher doses or in susceptible individuals.

Melanotan 2 and Hair Pigmentation

MC1R and MC2R activation by alpha-MSH analogs can in principle stimulate melanin synthesis in hair follicle melanocytes. Case reports and observational data from online user communities mention darkening of hair and increased freckling following MT-II use; the Gilhooley 2021 qualitative study documented these as commonly reported observations in forum discussions.^[7] Controlled hair-darkening studies in humans have not been published. No published trial has measured hair pigmentation as a primary or secondary endpoint.

Hepatic and Systemic Observations in Case Reports

Liver-specific toxicity has not been a primary finding in published MT-II case reports or trials. The documented case series focus on renal and cardiovascular adverse events. Liver function parameters were not a primary endpoint in the early clinical trials, and no published case series has identified hepatotoxicity as a signal in the MT-II adverse-event record. This absence of evidence should be interpreted carefully — it reflects the limited scale of the published safety literature, not a formal hepatic safety clearance.